Home › Non-Small Cell Lung Cancer › Missouri
Non-Small Cell Lung Cancer clinical trials in Missouri
84 studies for Non-Small Cell Lung Cancer are looking for participants at sites in Missouri.
Cities in Missouri
- St. Louis71 studies
- Kansas City31 studies
- Springfield10 studies
- Cape Girardeau9 studies
- Lee's Summit9 studies
- O'Fallon8 studies
- Columbia8 studies
- Joplin4 studies
- Saint Joseph3 studies
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Washington University Center for Advanced Medicine, St Louis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06765109A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Missouri Cancer Associates, Columbia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07361510Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Saint Francis Medical Center, Cape Girardeau
- Saint Luke's Hospital, Chesterfield
- and 18 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT04267848A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Missouri Cancer Associates, Columbia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07361497Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Saint Francis Medical Center, Cape Girardeau
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07388524A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07127874Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Washington University School of Medicine - Siteman Cancer Center, St Louis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06881784Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- University Health Truman Medical Center, Kansas City
- Mercy Hospital South, St Louis
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06498635A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Missouri Cancer Associates, Columbia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07144280A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Washington University School Of Medicine, St Louis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05498428Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06218914This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Saint Luke's Hospital of Kansas City, Kansas City
- Saint Luke's East Hospital, Lee's Summit
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06758401A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Bridgeton
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06868277A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Washington University School of Medicine, St Louis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07154290A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Truman Medical Ctr West, Kansas City
- Oncology Hematology Associates, Springfield
- Washington University School Of Medicine, St Louis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06667076Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Washington University, St Louis
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04981119A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Mercy South - David M Sindelar Cancer Center ( Site 0098), St Louis
- Mercy Research - David C. Pratt Cancer Center ( Site 0006), St Louis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06312137A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Washington University in St Louis, St Louis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06667908A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Washington University, School of Medicine, St Louis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06172478Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- and 18 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT03191149Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Missouri Baptist Medical Center, St Louis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06890598Pan-tumor MRD Study
- Cox Health, Springfield
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06605404A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
- Washington University School of Medicine, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07140016Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Kansas City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06357533A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Local Institution - 0140, St Louis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06618287A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Local Institution - 0498, Kansas City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06561386Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Washington University School of Medicine, St Louis
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07100080Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Missouri Cancer Associates, Columbia
- SSM Health Cancer Care - St. Clare, Fenton
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06712316A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Local Institution - 0685, Fenton
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06875310A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- St. Lukes Hosp. of Kansas City /ID# 259940, Kansas City
- Hulston Cancer Center /ID# 232226, Springfield
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT04928846Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
- Washington University School of Medicine, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT06529822Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Washington University, St Louis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05267626A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Bridgeton
- Research Site, Kansas City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06692738Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Kansas City
- Clinical Study Site, St Louis
- Clinical Study Site, St Louis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06767514A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Washington University School of Medicine, St Louis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06855771Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Washington University, St Louis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT05786924Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Washington University-School of Medicine /ID# 262759, St Louis
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06236438A Study of KK2269 in Adult Participants With Solid Tumors
- Washington University, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06266299A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
- Ellis Fischel Cancer Center, Columbia
- Siteman Cancer Center - Washington University Medical Campus, St Louis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT04302025Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- St. Lukes Hospital of Kansas City, Kansas City
- Washington University School of Medicine, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06625775From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.